Pfizer was developing axitinib (a tyrosine kinase inhibitor or TKI) for the treatment of pancreatic cancer. Unfortunately, recent Phase III results were disappointing. As a result, Pfizer has terminated development on this agent. This is just another failure example of all the money, time, and energy spent on drug development research. It really is a shame because we need more effective therapies in oncology.